November 3, 2011
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD
Thursday, November 3 |
|
| 8:00 am - 8:05 am | Welcome and Introductions Ignacio Melero, MD, PhD - University of Navarra |
| 8:05 am - 8:35 am | The CITN Perspective on Immunotherapy Combinations Martin A. "Mac" Cheever, MD - Principal Investigator, Cancer Immunotherapy Trials Network (CITN); Fred Hutchinson Cancer Research Center |
| 8:35 am - 10:10 am | Session I: Immunotherapy Combinations with Other Immunotherapies Chair: Ignacio Melero, MD, PhD - University of Navarra |
| 8:35 am - 8:40 am | Session Introduction Co-Chair: Ignacio Melero, MD, PhD - University of Navarra |
| 8:40 am - 9:00 am |  Differential Responses to Immunotherapy of Orthotopic Tumors Compared toSubcutaneous Tumors Michael H. Kershaw, PhD - Peter MacCallum Cancer Centre |
| 9:00 am - 9:20 am | Optimising Agonistic Antibodies to Promote Anti-Cancer Responses Martin J. Glennie, PhD, University of Southampton |
| 9:20 am - 9:40 am | PD-1 and CTLA-4 Combinations Gordon J. Freeman, PhD, Dana-Farber Cancer Institute |
| 9:40 am - 10:10 am | Panel Discussion and Audience Q&A |
| 10:10 am - 10:40 am | Break |
| 10:40 am - 12:15 pm | Session II: Immunotherapy Combinations with Conventional Cancer Therapies Chair: Hideho Okada, MD, PhD - University of Pittsburgh Cancer Institute |
| 10:40 am - 10:45 am | Session Introduction Co-Chair: Hideho Okada, MD, PhD, University of Pittsburgh Cancer Institute |
| 10:45 am - 11:05 am | Unraveling Novel Pathways of Immunogenic Cell Death and Their Clinical Implications Laurence Zitvogel, MD, PhD, Institute Gustave Roussy |
| 11:05 am - 11:25 am |  Translational Development of Therapeutic Vaccines for LymphomaLarry W. Kwak, MD, PhD, MD Anderson Cancer Center |
| 11:25 am - 11:45 am | Cancer Vaccine Combinations with Conventional Therapies Philip M. Arlen, MD, National Cancer Institute, NIH |
| 11:45 am - 12:15 pm | Panel Discussion and Audience Q&A |
| 12:15 pm - 1:15 pm | Lunch Break |
| 1:15 pm - 2:50 pm | Session III: Logistical Issues Chair: Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine |
| 1:15 pm - 1:20 pm | Session Introduction Co-Chair: Suzanne L. Topalian, MD, Johns Hopkins University School of Medicine |
| 1:20 pm - 1:40 pm | Regulatory Perspectives on Combinatorial Immunotherapies Raj K. Puri, MD, PhD, U.S. Food and Drug Administration, CBER |
| 1:40 pm - 2:00 pm | Developing Immunotherapy Combinations - Logistical Issues/Legal Matters David T. Bonk, JD, Bristol-Myers Squibb Company |
| 2:00 pm - 2:20 pm | Combinatorial Approaches to Immune Therapy of Cancer: Building on Recent Success F. Stephen Hodi, Jr., MD, Dana-Farber Cancer Institute |
| 2:20 pm - 2:50 pm | Panel Discussion and Audience Q&A |
| 2:50 pm - 3:20 pm | Break |
| 3:20 pm - 4:55 pm | Session IV: Clinical Trial Efforts: What Have We Learned? Chair: Alan J. Korman, PhD - Bristol-Myers Squibb Company |
| 3:20 pm - 3:25 pm | Session Introduction Co-Chair: Alan J. Korman, PhD, Bristol-Myers Squibb Company |
| 3:25 pm - 3:45 pm | Combination Immunotherapy and BRAF Targeted Therapy for Melanoma Antoni Ribas, MD, UCLA Medical Center |
| 3:45 pm - 4:05 pm | CD40 Immunotherapy for Cancer Robert H. Vonderheide, MD, DPhil, University of Pennsylvania |
| 4:05 pm - 4:25 pm | Combination of Antibody Against CD137 with Other Anti Cancer Antibodies Ronald Levy, MD, Stanford University School of Medicine |
| 4:25 pm - 4:55 pm | Panel Discussion and Audience Q&A |
| 4:55 pm - 5:00 pm | Closing Comments Alan J. Korman, PhD - Bristol-Myers Squibb Company |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
